Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0005227235
Thu, 26.08.2021
Biotest AG
PRESS RELEASE
Biotest receives approval for phase III clinical trial in pregnant women for prevention of CMV infection of the unborn baby
Infection of the foetus with Cytomegalovirus (CMV) may cause developmental retardation and hearing loss of the new born
High unmet medical need due to large amount of babies born with CMV-related disorders
Si [ … ]
Mon, 23.08.2021
Biotest AG
PRESS RELEASE
Biotest AG opens sixth plasma collection centre in Czech Republic
26 plasma collection centres in Europe to ensure long-term plasma supply
Dreieich, 23 August 2021. Biotest has received the operating license for its sixth plasma collection centre in Czech Republic from the country's national public health authority SUKL. The centre [ … ]
Fri, 13.08.2021
Biotest AG
PRESS RELEASE
Trimodulin does not reach the primary endpoint in the phase II trial in patients with severe COVID-19
First results do neither show an improvement in the course of the disease nor in mortality compared to the placebo group.
Trimodulin still demonstrates a good safety profile
Biotest does not aim for approval in COVID-19
Dreie [ … ]
Thu, 12.08.2021
Biotest AG
PRESS RELEASEBiotest increases sales by 10% in the first half of 2021
- Increase in plasma collection centres to 25 in Europe
- Manufacturing authorization for expansion project Biotest Next Level granted
- Guidance confirmed
Dreieich, 12 August 2021. In the first half of financial year 2021, the Biotest Group recorded a revenue in the amount o [ … ]
Tue, 03.08.2021
Biotest AG
PRESS RELEASE
Biotest proves the mode of action of trimodulin for the treatment of COVID-19
- Trimodulin limits pathological inflammatory responses
- Two new preclinical studies published on the mode of action of trimodulin in COVID-19
- Results of a prospective, double-blind, placebo-controlled Phase II study in severely ill COVID-19 patient [ … ]
Tue, 20.07.2021
Biotest AG
PRESS RELEASE
Biotest AG opens 11th plasma collection centre in Hungary
- 25 plasma collection centres in Europe to ensure long-term plasma supply
Dreieich, 20 July 2021. Biotest received an operating permit for its 11th plasma collection centre in Hungary from the country's national public health authority OTH. The centre is located in a shoppi [ … ]
Tue, 13.07.2021
Biotest AG
PRESS RELEASE
Biotest receives manufacturing license for new production facility and plans to hire 150 additional employees
- Final inspection by the Darmstadt Regional Council and the Paul Ehrlich Institute successfully completed
- Start of routine production and ramp-up of the plants is initiated
- 150 additional employees are sought
Dreieic [ … ]
Wed, 30.06.2021
Biotest AG
PRESS RELEASE
Biotest AG opens fifth plasma collection centre in Czech Republic
- 24 plasma collection centres in Europe to ensure long-term plasma supply
Dreieich, 30 June 2021. Biotest has received the operating license for its fifth plasma collection centre in Czech Republic from the country's national public health authority SUKL. The centre [ … ]
Wed, 02.06.2021
Biotest AG
PRESS RELEASE
Biotest successfully completes recruitment for its clinical trial with trimodulin in severe COVID-19 patients
- Trimodulin as potential life-saving treatment for severe COVID-19 patients
- All 166 trial patients treated by end of June, first results expected for August 2021
- Positive recommendation from Data Safety and Monitori [ … ]
Tue, 11.05.2021
Biotest AG
PRESS RELEASE
Biotest AG: Annual General Meeting approves dividend distribution
- Distribution of EUR 0.04 per preferred share
- Broad majority on all agenda items in accordance with the proposals of the management (Verwaltung)
Dreieich 11 May 2021. At the second ordinary, virtual Annual General Meeting on 11 May 2021, the shareholders of Biote [ … ]